Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Lynparza for Ovarian Cancer

FDA news release; 2017 Aug 17

The FDA has approved Lynparza (olaparib) for the maintenance treatment of patients with ovarian cancer.

Indications: Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.

Dosage and administration: 300 mg taken orally twice daily with or without food.

Efficacy and safety: Approval is based on results of 2 randomized, placebo-controlled, double-blind, multicenter trials which demonstrated statistically significant improvement in progression-free survival in patients receiving Lynparza, vs those treated with placebo.

Side effects/risks: The most common adverse reactions are anemia, nausea, fatigue, vomiting, nasopharyngitis/upper respiratory tract infection/influenza, diarrhea, arthralgia/myalgia, dysgeusia, headache, dyspepsia, decreased appetite, constipation, and stomatitis.

Citation:

FDA approves olaparib tablets for maintenance treatment in ovarian cancer [news release]. Silver Spring, MD: FDA. August 17, 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm572143.htm. Accessed August 27, 2017.

Lynparza [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208558s000lbl.pdf. Accessed August 27, 2017.

This Week's Must Reads

First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.

Inadequate emergency care a challenge for rural pediatric patients, Walling EB et al. J Oncol Pract. 2019 Jan 31. doi: 10.1200/JOP.18.00115.

QC measures improve with CMS Oncology Care Model, Rocque G et al. J Oncol Pract. 2019. doi: 10. 1200/JOP.18.00390.

Must Reads in Gynecologic Cancer

Uterine serous carcinoma patients have continuous high risk of VTE , Gressel GM et al. Obstet Gynecol. 2018 Oct 5;132:1130-6.

CD8+ Tumor-Infiltrating Lymphocytes and Ovarian Ca, JAMA Oncol; ePub 2017 Oct 12; OTTA Consortium

Lymph Node Removal During Endometrial Ca Surgery, Cochrane; 2017 Oct 2; Frost, Webster, et al

Cochrane on Reducing Neoplasia in Molar Pregnancy, Cochrane; 2017 Sep 11; Wang, Fu, Hu, et al

FDA Approves First Biosimilar to Treat Cancer, FDA news release; 2017 Sep 14